Resistance of CD-1 and ogg1 DNA repair-deficient mice to thalidomide and hydrolysis product embryopathies in embryo culture

Toxicological Sciences

Volumn 122, Issue 1, 2011, Pages 146-156

  Lee, Crystal J J ^a   Goncxalves, Luisa L ^a,b   Wells, Peter G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTO SUPERIOR DE CIÊNCIAS DA SAÚDE EGAS MONIZ   (Portugal)

Author keywords

DNA repair; Embryopathies; Hydrolysis products; Mouse embryo culture; Oxoguanine glycosylase 1; Thalidomide

Indexed keywords

2 PHTHALIMIDOGLUTARAMIC ACID; 2 PHTHALIMIDOGLUTARIC ACID; 8 HYDROXYGUANINE; DNA GLYCOSYLTRANSFERASE; DRUG METABOLITE; OXOGUANINE GLYCOSYLASE 1; THALIDOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH DEFECT; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EXPOSURE; DRUG HYDROLYSIS; DRUG SPECIFICITY; EMBRYO; EMBRYO CULTURE; EMBRYOPATHY; FEMALE; GENETIC RESISTANCE; KNOCKOUT MOUSE; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; SPECIES DIFFERENCE; TERATOGENESIS;

MUS; ORYCTOLAGUS CUNICULUS; RATTUS;

EID: 79960187844     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr084     Document Type: Article

References (51)

1. Ando, Y., Fuse, E., and Figg, W. D. (2002). Thalidomide metabolism by the CYP2C subfamily. Clin. Cancer Res. 8, 1964-1973.
2. Arlen, R. R., and Wells, P. G. (1996). Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharmacol. Exp. Ther. 277, 1649-1658.
3. Augustine-Rauch, K. A., Zhang, Q., Kleinman, M., Lawton, R., and Welsh, M. J. (2004). A study of vehicles for dosing rodent whole embryo culture with non-aqueous soluble compounds. Reprod. Toxicol. 18, 391-398.
4. Bhuller, Y., Jeng, W., and Wells, P. G. (2006). Variable in vivo embryoprotective role for ataxia telangiectasia-mutated (Atm) against endogenous and phenytoin-enhanced oxidative stress in Atm knockout mice. Toxicol. Sci. 93, 146-155.
5. Bhuller, Y., and Wells, P. G. (2006). A developmental role for antaxiatelangiectasia mutated (ATM) in protecting the embryo from spontaneous and phenytoin-enhanced embryopathies in culture. Toxicol. Sci. 93, 155-163.
6. Braun, A. G., Harding, F. A., and Weinreb, S. L. (1986). Teratogen metabolism: thalidomide activation is mediated by cytochrome P-450. Toxicol. Appl. Pharmacol. 82, 175-179.
7. Castilla, E. E., Ashton-Prolla, P., Barreda-Mejia, E., Brunoni, D., Cavalcanti, D. P., Correa-Neto, J., Delgadillo, J. L., Dutra, M. G., Felix, T., Giraldo, A., et al. (1996). Thalidomide, a current teratogen in South America. Teratology 54, 273-277.
8. Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M., and Ching, L. M. (2004). Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin. Cancer Res. 10, 5949-5956.
9. Delahunt, C. S., and Lassen, L. J. (1964). Thalidomide syndrome in monkeys. Science 146, 1300-1305.
10. Fabro, S., Schumacher, H., Smith, R. L., and Williams, R. T. (1964). Identification of thalidomide in rabbit blastocysts. Nature 201, 1125-1126.
11. Fabro, S., and Smith, R. L. (1966). The teratogenic activity of thalidomide in the rabbit. J. Pathol. Bacteriol. 91, 511-519.
12. Fabro, S., Smith, R. L., and Williams, R. T. (1967a). The fate of [14C]thalidomide in the pregnant rabbit. Biochem. J. 104, 565-569.
13. Fabro, S., Smith, R. L., and Williams, R. T. (1967b). The fate of the hydrolysis products of thalidomide in the pregnant rabbit. Biochem. J. 104, 570-574.
14. Gordon, G. B., Spielberg, S. P., Blake, D. A., and Balasubramanian, V. (1981). Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc. Natl. Acad. Sci. U.S.A. 78, 2545-2548.
15. Hansen, J. M., Carney, E. W., and Harris, C. (1999). Differential alteration by thalidomide of the glutathione content of rat vs. rabbit conceptuses in vitro. Reprod. Toxicol. 13, 547-554.
16. Hansen, J. M., Gong, S. G., Philbert, M., and Harris, C. (2002a). Misregulation of gene expression in the redox-sensitive NF-kappaB-dependent limb outgrowth pathway by thalidomide. Dev. Dyn. 225, 186-194.
17. Hansen, J. M., Harris, K. K., Philbert, M. A., and Harris, C. (2002b). Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. J. Pharmacol. Exp. Ther. 300, 768-776.
18. Hendrickx, A. G., and Newman, L. (1973). Appendicular skeletal and visceral malformations induced by thalidomide in bonnet monkeys. Teratology 7, 151-160.
19. Huang, P. H., McBride, W. G., and Tuman, W. G. (1999). Interaction of thalidomide with DNA of rabbit embryos: a possible explanation for its immunosuppressant and teratogenic effects. Pharmacol. Toxicol. 85, 103-104.
20. Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., and Handa, H. (2010). Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350.
21. Kasapinovic, S., McCallum, G. P., Wiley, M. J., and Wells, P. G. (2004). The peroxynitrite pathway in development: phenytoin and benzo[a]pyrene embryopathies in inducible nitric oxide synthase (iNOS) knockout mice. Free Radic. Biol. Med. 37, 1702-1711.
22. King, F. E., and Kidd, D. A. A. (1949). A new synthesis of glutamine and c-dipeptides of glutamic acid from phthalyated intermediates. J. Chem. Soc. 3315-3319.
23. Kitchin, K. T., and Ebron, M. T. (1984). Further development of rodent whole embryo culture: solvent toxicity and water insoluble compound delivery system. Toxicology 30, 45-57.
24. Klungland, A., Rosewell, I., Hollenbach, S., Larsen, E., Daly, G., Epe, B., Seeberg, E., Tomas, L., and Barnes, D. E. (1999). Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc. Natl. Acad. Sci. U.S.A. 96, 13300-13305.
25. Knobloch, J., Reimann, K., Klotz, L., and Ruther, U. (2008a). Thalidomide resistance is based on the capacity of the glutathione-dependent antioxidant defense. Mol. Pharm. 5, 1138-1144.
26. Knobloch, J., Schmitz, I., Gotz, K., Schulze-Osthoff, K., and Ruther, U. (2008b). Thalidomide induces limb anomalies in PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol. Cell Biol. 28, 529-538.
27. Knobloch, J., Shaughnessy, J. D., and Ruther, U. (2007). Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J. 21, 1410-1421.
28. Lee, C. J. J., Goncxalves, L. L., and Wells, P. G. (2011). Embryopathic effects of thalidomide and its hydrolysis products in rabbit embryo culture: evidence for a prostaglandin H synthase (PHS)-dependent, reactive oxygen species (ROS)-mediated mechanism. FASEB J. Advance Access published on April 18, 2011; doi:10.1096/fj.10-178814.
29. Lenz, W. (1988). A short history of thalidomide embryopathy. Teratology 38, 203-215.
30. Matthews, S. J., and McCoy, C. (2003). Thalidomide: a review of approved and investigational uses. Clin. Ther. 25, 342-395.
31. McBride, W. G. (1977). Thalidomide embryopathy. Teratology 16, 79-82.
32. McCallum, G. P., Wong, A. W., and Wells, P. G. (2011). Cockayne syndrome B (CSB) protects against methamphetamine-enhanced oxidative DNA damage in murine fetal brain and postnatal neurodevelopmental deficits. Antioxid. Redox Signal. 14, 747-756.
33. Miller, L., and Wells, P. G. (2011). Altered methanol embryopathies in embryo culture with mutant catalase-deficient mice and transgenic mice expressing human catalase. Toxicol. Appl. Pharmacol. 252, 55-61.
34. Parman, T., Wiley, M. J., and Wells, P. G. (1999). Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med. 5, 582-585.
35. Perez-Pasten, R., Martinez-Galero, E., Garduno-Siciliano, L., Conde Lara, I., and Chamorro Cevallos, G. (2006). Effects of dimethylsulphoxide on mice arsenite-induced dysmorphogenesis in embryo culture and cytotoxicity in embryo cells. Toxicol. Lett. 161, 167-173.
36. Sauer, H., Gunther, J., Hescheler, J., and Wartenberg, M. (2000). Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol. 156, 151-158.
37. Schuler-Faccini, L., Soares, R. C. F., de Sousa, A. C. M., Maximino, C., Luna, E., Schwartz, I. V. D., Waldman, C., and Castilla, E. E. (2007). New cases of thalidomide embryopathy in Brazil. Birth Defects Res. A 79, 671-672.
38. Schumacher, H., Blake, D. A., and Gillette, J. R. (1968a). Disposition of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160, 201-211.
39. Schumacher, H., Blake, D. A., Gurian, J. M., and Gillette, J. R. (1968b). A comparison of the teratogenic activity of thalidomide in rabbits and rats. J. Pharmacol. Exp. Ther. 160, 189-200.
40. Schumacher, H., Smith, R. L., and Williams, R. T. (1965). The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br. J. Pharmacol. 25, 338-351.
41. Schumacher, H. J., Wilson, J. G., Terapane, J. F., and Rosedale, S. L. (1970). Thalidomide: disposition in rhesus monkey and studies of its hydrolysis in tissues of this and other species. J. Pharmacol. Exp. Ther. 173, 265-269.
42. Scott, W. J., Fradkin, R., and Wilson, J. G. (1977). Non-confirmation of thalidomide induced teratogenesis in rats and mice. Teratology 16, 333-335.
43. Silverstein, R. M., Bassier, G. C., and Morril, T. C. (1991). In Spectrometric Identification of Organic Compounds. John Wiley & Sons, Inc., New York, NY.
44. Siu, M., and Wells, P. G. (2010). Catalase in the mechanism of methanol developmental toxicity. Toxicol. Sci. 114(Suppl. The Toxicologist), 183 (Abstract No. 858).
45. Somers, G. F. (1962). Thalidomide and congenital abnormalities. Lancet 279, 912-913.
46. Stephens, T. D., Bunde, C. J. W., and Fillmore, B. J. (2000). Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol. 59, 1489-1499.
47. Theiler, K. (1989). In The House Mouse: Atlas of Embryonic Development. Springer-Verlag, New York, NY.
48. Wells, P. G., McCallum, G. P., Chen, C. S., Henderson, J. T., Lee, C. J. J., Perstin, J., Preston, T. J., Wiley, M. J., and Wong, A. W. (2009). Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol. Sci. 108, 4-18.
49. Wells, P. G., McCallum, G. P., Lam, K. C. H., Henderson, J. T., Ondovcik, S. L., Preston, T. J., Wiley, M. J., and Wong, A. W. (2010). Oxidative DNA damage and repair in teratogenesis and neurodevelopmental deficits. Birth Defects Res. C 90, 103-109.
50. Williams, R. T. (1968). Thalidomide. A study of biochemical teratology. Arch. Environ. Health 16, 493-502.
51. Winn, L. M., and Wells, P. G. (1995). Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen speciesmediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 48, 112-120.